Genmab A/S
GMAB evidence brief
What we can confirm
- Market Cap:
- $20.02B
What it means
What to watch
Prepared research question
What matters most for GMAB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GMAB
Genmab A/S is a Danish biotechnology company focused on developing innovative antibody-based therapies for cancer and other serious diseases, with a pipeline spanning approved products and late-stage experimental programs such as Rina-S and petosemtamab.
Key risk: Industry-wide uncertainties
Market Cap
$20.02B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Tracking 28 clinical trials for Genmab A/S.
Genmab A/S is a Danish biotechnology company focused on developing innovative antibody-based therapies for cancer and other serious diseases, with a pipeline spanning approved products and late-stage experimental programs such as Rina-S and petosemtamab.
- Cash & equivalents of $1,715.0M as of 2025-12-31 [sec].
- Total employees of 3,119 as of June 30, 2026, up from 2,639 a year earlier, reflecting R&D expansion and the acquisition of Merus [sec · filed 2026-08-06].
- Rina-S, a FRα-directed TOPO1 ADC, has received FDA Breakthrough Therapy designation for recurrent or progressive endometrial cancer (August 2025) and Fast Track designation for FRα-expressing high-grade serous or endometrioid PROC (January 2024) [sec · filed 2026-08-06].
- Petosemtamab is being evaluated in a Phase 3 trial (NCT06496178) in 2L/3L recurrent/metastatic HNSCC and in a Phase 2 study (NCT03526835) for other advanced solid tumors [sec · filed 2026-08-06].
- In November 2025, Merus entered a global collaboration and license agreement with Halozyme to develop a subcutaneous formulation of petosemtamab [sec · filed 2026-08-06].
What works
- Strong cash position of $1,715.0M as of 2025-12-31 provides financial flexibility for R&D and commercialization [sec].
- Multiple late-stage programs (Rina-S, petosemtamab, EPKINLY) with registrational readouts expected in 2026, indicating a rich pipeline [news · published 2026-03-18].
- Rina-S has received FDA Breakthrough Therapy and Fast Track designations, suggesting regulatory recognition of its potential [sec · filed 2026-08-06].
- The company has over 25 years of experience and a broad preclinical pipeline based on proprietary technologies [sec · filed 2026-08-06].
What to weigh
- As a biotech company, Genmab faces significant risks and uncertainties common to the industry, including operational, IP, R&D, commercialization, and financial risks [sec · filed 2026-08-06].
- The financial guidance for 2026 assumes no significant new agreements that could materially affect results, highlighting sensitivity to partnership outcomes [sec · filed 2026-08-06].
- Currency exchange rate fluctuations (USD/DKK) and changing inflation rates are noted as uncertainties that could impact net sales and royalties [sec · filed 2026-08-06].
- The company's employee count increased significantly (from 2,639 to 3,119) partly due to the Merus acquisition, which may indicate integration costs and operational complexity [sec · filed 2026-08-06].
From the filings
Quoted directly from source documents.
Rina-S FDA Breakthrough Therapy designation for endometrial cancer
“In August 2025, the FDA granted BTD for recurrent or progressive endometrial cancer.”
SEC filings · August 6, 2026
Registrational readouts expected in 2026
“Genmab outlines late-stage clinical catalysts for 2026 with registrational readouts for EPKINLY, Rina-S and petosemtamab”
News · March 18, 2026
Catalyst timeline
- 2025-02-07 · Phase 3 start for Rina-S in platinum-resistant ovarian cancer — A randomized, open-label study of Rina-S versus investigator's choice in patients with platinum-resistant ovarian cancer.
- 2021-01-13 · Phase 3 start for epcoritamab in R/R DLBCL — A randomized, open-label trial of epcoritamab vs investigator's choice chemotherapy in relapsed/refractory diffuse large B-cell lymphoma.
- 2019-09-17 · Phase 2 start for GEN1042 in malignant solid tumors — First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety and anti-tumor activity.
- 2025-01-29 · Phase 1 start for GEN1078 in malignant solid tumors — First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety and preliminary efficacy.
Risks & what to watch (3)›
Key risks
- Industry-wide uncertainties — Operational, IP, R&D, commercialization, and financial risks common to biotech [sec · filed 2026-08-06].
- Currency and inflation exposure — Net sales and royalties affected by USD/DKK exchange rate and inflation changes [sec · filed 2026-08-06].
- Dependence on partnership outcomes — 2026 guidance assumes no significant new agreements that could materially affect results [sec · filed 2026-08-06].
What to watch
- Registrational readouts for EPKINLY, Rina-S, and petosemtamab expected in 2026 [news · published 2026-03-18].
- Phase 3 RAINFOL-02 trial for Rina-S in platinum-resistant ovarian cancer completed enrollment in March 2026 [sec · filed 2026-08-06].
- Development of subcutaneous formulation of petosemtamab under the Halozyme collaboration [sec · filed 2026-08-06].
- Multiple new IND applications expected to be submitted for early-stage and preclinical programs [sec · filed 2026-08-06].
Sources: Catalysts · News · SEC filings · Generated October 13, 2026 · How we verify sources →
Run Genmab A/S through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Genmab A/S facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
271
Total value held
$2.23B
| Holder | Shares | Value |
|---|---|---|
| orbis allan gray ltd | 12,925,578 | $346.8M |
| alliancebernstein l.p. | 9,557,149 | $294.4M |
| paradigm biocapital advisors lp | 7,967,836 | $213.8M |
| arrowstreet capital, limited partnership | 4,975,324 | $133.5M |
| blackrock, inc. | 4,536,565 | $121.7M |
| renaissance technologies llc | 4,414,550 | $118.4M |
| deep track capital, lp | 3,663,250 | $98.3M |
| harding loevner lp | 3,231,601 | $86.7M |
| deerfield management company, l.p. | 2,462,000 | $66.1M |
| first trust advisors lp | 2,461,342 | $66.0M |
Showing top 10 of 271 institutional holders of Genmab A/S. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 1.4%
- Days to cover
- 5.3
- Shares short
- 8,576,449
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GMAB short interestGovernance
Frequently asked questions
What is the AI investment thesis for Genmab A/S?
Genmab A/S is a Danish biotechnology company focused on developing innovative antibody-based therapies for cancer and other serious diseases, with a pipeline spanning approved products and late-stage experimental programs such as Rina-S and petosemtamab.
Who is the CEO of Genmab A/S?
Dr. Jan G.J. van de Winkel Ph.D. is the chief executive officer of Genmab A/S (GMAB).
Where is Genmab A/S headquartered?
Genmab A/S (GMAB) is headquartered in Copenhagen, Denmark.
What therapeutic areas does Genmab A/S focus on?
Genmab A/S develops therapies across Oncology, Immunology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.